Cell Manufacturing and Immunoengineering Seminar

Event Details
  • Date/Time:
    • Friday December 8, 2017
      11:00 am - 12:00 pm
  • Location: Petit Biotechnology Building, Suddath Seminar Room 1128, Atlanta, GA
  • Phone:
  • URL:
  • Email:
  • Fee(s):
    N/A
  • Extras:
Contact
No contact information submitted.
Summaries

Summary Sentence: "Chimeric Antigen Receptor T Cells: Clinical Development, FDA Approval, and What’s Coming Next" - Bruce Levine, Ph.D., University of Pennsylvania

Full Summary: No summary paragraph submitted.

"Chimeric Antigen Receptor T Cells: Clinical Development, FDA Approval, and What’s Coming Next"

Bruce Levine, Ph.D.
Barbara and Edward Netter Professor in Cancer Gene Therapy
University of Pennsylvania Perelman School of Medicine

Since the 1990’s, we have conducted clinical trials of gene modified T cells. Chimeric antigen receptor (CAR) T cells targeting CD19 on B cells leukemias and lymphomas have induced durable complete responses in patients who are relapsed or refractory to all other available treatments. 

This synthetic biology technology has now undergone global multi-center clinical trials and recently received FDA approval (KymriahTM, Novartis) in relapsed/refractory acute lymphoid leukemia in children and young adults. CAR T cells targeting new targets in hematologic malignancies and in solid tumors are underway and provide demonstration that it is possible to design immunity at will for therapeutic application.  

Additional Information

In Campus Calendar
Yes
Groups

Parker H. Petit Institute for Bioengineering and Bioscience (IBB), Wallace H. Coulter Dept. of Biomedical Engineering

Invited Audience
Faculty/Staff, Public, Graduate students, Undergraduate students
Categories
Seminar/Lecture/Colloquium
Keywords
go-PetitInstitute, go-immuno, go-rem-events
Status
  • Created By: Angela Ayers
  • Workflow Status: Published
  • Created On: Oct 11, 2017 - 2:02pm
  • Last Updated: Oct 12, 2017 - 2:44pm